In conclusion, proliferative markers including Ki‐67, PCNA, PHH3 and Cyclin D1 have demonstrated promise as predictive and prognostic biomarkers in the context of pancreatic cancer chemotherapy. This evidence concerns the gene CCND1 and familial pancreatic carcinoma.